IL284670B2 - תערובת של מרכיבים פפטידיים להתחדשות וריפוי עור ושימושה - Google Patents
תערובת של מרכיבים פפטידיים להתחדשות וריפוי עור ושימושהInfo
- Publication number
- IL284670B2 IL284670B2 IL284670A IL28467021A IL284670B2 IL 284670 B2 IL284670 B2 IL 284670B2 IL 284670 A IL284670 A IL 284670A IL 28467021 A IL28467021 A IL 28467021A IL 284670 B2 IL284670 B2 IL 284670B2
- Authority
- IL
- Israel
- Prior art keywords
- peptide
- healing
- matrix
- mixture
- skin
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 158
- 239000000203 mixture Substances 0.000 title claims description 108
- 230000035876 healing Effects 0.000 title claims description 86
- 239000004615 ingredient Substances 0.000 title description 9
- 230000036560 skin regeneration Effects 0.000 title description 4
- 239000011159 matrix material Substances 0.000 claims description 70
- 235000001014 amino acid Nutrition 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 25
- 102000008186 Collagen Human genes 0.000 claims description 18
- 108010035532 Collagen Proteins 0.000 claims description 18
- 229920001436 collagen Polymers 0.000 claims description 18
- 235000018102 proteins Nutrition 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- NZWIFMYRRCMYMN-UHFFFAOYSA-N copper;6-amino-2-[[2-[(2-aminoacetyl)amino]-3-(1h-imidazol-5-yl)propanoyl]amino]hexanoic acid Chemical group [Cu+2].NCCCCC(C(O)=O)NC(=O)C(NC(=O)CN)CC1=CN=CN1 NZWIFMYRRCMYMN-UHFFFAOYSA-N 0.000 claims description 13
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 claims description 11
- 230000029663 wound healing Effects 0.000 claims description 11
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 6
- 239000004475 Arginine Substances 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- 229920002674 hyaluronan Polymers 0.000 claims description 6
- 229960003160 hyaluronic acid Drugs 0.000 claims description 6
- -1 arginine amino acid Chemical class 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- CUVSTAMIHSSVKL-UWVGGRQHSA-N (4s)-4-[(2-aminoacetyl)amino]-5-[[(2s)-6-amino-1-(carboxymethylamino)-1-oxohexan-2-yl]amino]-5-oxopentanoic acid Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN CUVSTAMIHSSVKL-UWVGGRQHSA-N 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 230000007547 defect Effects 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- 230000002500 effect on skin Effects 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- LTRSPDHUDXWHRY-UHFFFAOYSA-N 8-methyl-6,9-diazaspiro[4.5]decane-7,10-dione Chemical compound N1C(=O)C(C)NC(=O)C11CCCC1 LTRSPDHUDXWHRY-UHFFFAOYSA-N 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims 1
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- 108010091287 palmitoyl-glycyl-histidyl-lysine Proteins 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 description 86
- 206010052428 Wound Diseases 0.000 description 84
- 238000002360 preparation method Methods 0.000 description 56
- 239000000843 powder Substances 0.000 description 52
- 210000003491 skin Anatomy 0.000 description 50
- 239000000499 gel Substances 0.000 description 45
- 102000004196 processed proteins & peptides Human genes 0.000 description 38
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 31
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 26
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 22
- 238000009472 formulation Methods 0.000 description 22
- 229940024606 amino acid Drugs 0.000 description 20
- 239000002537 cosmetic Substances 0.000 description 18
- 206010012601 diabetes mellitus Diseases 0.000 description 17
- 229940099259 vaseline Drugs 0.000 description 16
- 108010036999 aspartyl-alanyl-histidyl-lysine Proteins 0.000 description 15
- 238000010172 mouse model Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 229930064664 L-arginine Natural products 0.000 description 11
- 235000014852 L-arginine Nutrition 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 230000001684 chronic effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 239000004201 L-cysteine Substances 0.000 description 9
- 235000013878 L-cysteine Nutrition 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000037303 wrinkles Effects 0.000 description 9
- 239000001828 Gelatine Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 230000008929 regeneration Effects 0.000 description 7
- 238000011069 regeneration method Methods 0.000 description 7
- 102000016942 Elastin Human genes 0.000 description 6
- 108010014258 Elastin Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 235000010443 alginic acid Nutrition 0.000 description 6
- 229920000615 alginic acid Polymers 0.000 description 6
- 229920002549 elastin Polymers 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- ZHMCDZHVHDFSHO-UHFFFAOYSA-N undecane-2,5-dione Chemical compound CCCCCCC(=O)CCC(C)=O ZHMCDZHVHDFSHO-UHFFFAOYSA-N 0.000 description 6
- 235000009697 arginine Nutrition 0.000 description 5
- 229960003121 arginine Drugs 0.000 description 5
- 239000000679 carrageenan Substances 0.000 description 5
- 235000010418 carrageenan Nutrition 0.000 description 5
- 229920001525 carrageenan Polymers 0.000 description 5
- 229940113118 carrageenan Drugs 0.000 description 5
- SMKDPQDICUEFRX-UHFFFAOYSA-N dodecane-2,5-dione Chemical compound CCCCCCCC(=O)CCC(C)=O SMKDPQDICUEFRX-UHFFFAOYSA-N 0.000 description 5
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 description 5
- 238000009499 grossing Methods 0.000 description 5
- 239000001272 nitrous oxide Substances 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 4
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 4
- 108010011459 Exenatide Proteins 0.000 description 4
- 102000008946 Fibrinogen Human genes 0.000 description 4
- 108010049003 Fibrinogen Proteins 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 229940072056 alginate Drugs 0.000 description 4
- 238000002266 amputation Methods 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 4
- 239000001639 calcium acetate Substances 0.000 description 4
- 235000011092 calcium acetate Nutrition 0.000 description 4
- 229960005147 calcium acetate Drugs 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 229960001519 exenatide Drugs 0.000 description 4
- 229940012952 fibrinogen Drugs 0.000 description 4
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 4
- 229940124280 l-arginine Drugs 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000004246 zinc acetate Substances 0.000 description 4
- LTRSPDHUDXWHRY-LURJTMIESA-N (8s)-8-methyl-6,9-diazaspiro[4.5]decane-7,10-dione Chemical compound N1C(=O)[C@H](C)NC(=O)C11CCCC1 LTRSPDHUDXWHRY-LURJTMIESA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 206010048554 Endothelial dysfunction Diseases 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 3
- 102000005741 Metalloproteases Human genes 0.000 description 3
- 108010006035 Metalloproteases Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000016611 Proteoglycans Human genes 0.000 description 3
- 108010067787 Proteoglycans Proteins 0.000 description 3
- 208000000558 Varicose Ulcer Diseases 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 230000008694 endothelial dysfunction Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 3
- 239000011654 magnesium acetate Substances 0.000 description 3
- 229940069446 magnesium acetate Drugs 0.000 description 3
- 235000011285 magnesium acetate Nutrition 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- GTAWIGQAZOWHAW-UHFFFAOYSA-N tridecane-2,5-dione Chemical compound CCCCCCCCC(=O)CCC(C)=O GTAWIGQAZOWHAW-UHFFFAOYSA-N 0.000 description 3
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 2
- 206010004950 Birth mark Diseases 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 241001340526 Chrysoclista linneella Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 2
- 229930028154 D-arginine Natural products 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
- 229920002230 Pectic acid Polymers 0.000 description 2
- 208000004210 Pressure Ulcer Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 241000212749 Zesius chrysomallus Species 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- 238000002316 cosmetic surgery Methods 0.000 description 2
- 108010040486 cyclo(alanine-(1-amino-1-cyclopentane)carbonyl) Proteins 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000004426 flaxseed Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000009442 healing mechanism Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000002406 microsurgery Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- FPJHWYCPAOPVIV-VOZMEZHOSA-N (2R,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-5-acetamido-2-(hydroxymethyl)-6-methoxy-3-sulfooxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CO[C@@H]1O[C@H](CO)[C@H](OS(O)(=O)=O)[C@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2O)C(O)=O)[C@H]1NC(C)=O FPJHWYCPAOPVIV-VOZMEZHOSA-N 0.000 description 1
- LODWEXDBRZBADB-XEVVZDEMSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-methylbutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O LODWEXDBRZBADB-XEVVZDEMSA-N 0.000 description 1
- RJZNPROJTJSYLC-LLINQDLYSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O RJZNPROJTJSYLC-LLINQDLYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- XFRVVPUIAFSTFO-UHFFFAOYSA-N 1-Tridecanol Chemical compound CCCCCCCCCCCCCO XFRVVPUIAFSTFO-UHFFFAOYSA-N 0.000 description 1
- JWSDUZPHHXIUBR-UHFFFAOYSA-N 4-oxooctanal Chemical compound CCCCC(=O)CCC=O JWSDUZPHHXIUBR-UHFFFAOYSA-N 0.000 description 1
- LVHMYEDFLUCWTN-UHFFFAOYSA-N 6-hexadecanoyl-8-methyl-6,9-diazaspiro[4.5]decane-7,10-dione Chemical compound C(CCCCCCCCCCCCCCC)(=O)N1C2(CCCC2)C(NC(C1=O)C)=O LVHMYEDFLUCWTN-UHFFFAOYSA-N 0.000 description 1
- YCGHYRDZGVZGBK-UHFFFAOYSA-N 7-ethyl-5-propyl-5,8-diazaspiro[3.5]nonane-6,9-dione Chemical compound CCCN1C(=O)C(NC(=O)C12CCC2)CC YCGHYRDZGVZGBK-UHFFFAOYSA-N 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 description 1
- 102000004237 Decorin Human genes 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 229930195710 D‐cysteine Natural products 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- NOOJLZTTWSNHOX-UWVGGRQHSA-N Melanostatin Chemical compound NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 NOOJLZTTWSNHOX-UWVGGRQHSA-N 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108010013296 Sericins Proteins 0.000 description 1
- 229920002334 Spandex Polymers 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000004904 UV filter Substances 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- NENOAJSZZPODGJ-OIMNJJJWSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] octanoate Chemical compound CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NENOAJSZZPODGJ-OIMNJJJWSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940076286 cupric acetate Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 238000011542 limb amputation Methods 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 108700039855 mouse a Proteins 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229940094912 palmitoyl tripeptide-5 Drugs 0.000 description 1
- 230000026792 palmitoylation Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 210000000438 stratum basale Anatomy 0.000 description 1
- 210000000498 stratum granulosum Anatomy 0.000 description 1
- 210000000437 stratum spinosum Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 229940100613 topical solution Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229940087291 tridecyl alcohol Drugs 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229960000314 zinc acetate Drugs 0.000 description 1
- 235000013904 zinc acetate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/58—Metal complex; Coordination compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ201934A CZ308845B6 (cs) | 2019-01-21 | 2019-01-21 | Farmaceutická směs topicky hojivých peptidových složek pro použití k topické léčbě kožních defektů a/nebo k topickému hojení ran |
| PCT/IB2020/050418 WO2020152568A1 (en) | 2019-01-21 | 2020-01-20 | Skin renewing and healing mixture of peptide components and its use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL284670A IL284670A (he) | 2021-08-31 |
| IL284670B1 IL284670B1 (he) | 2024-07-01 |
| IL284670B2 true IL284670B2 (he) | 2024-11-01 |
Family
ID=71736281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL284670A IL284670B2 (he) | 2019-01-21 | 2020-01-20 | תערובת של מרכיבים פפטידיים להתחדשות וריפוי עור ושימושה |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3914279A1 (he) |
| JP (1) | JP7193662B2 (he) |
| KR (1) | KR20210120026A (he) |
| CN (1) | CN113301910B (he) |
| CZ (1) | CZ308845B6 (he) |
| IL (1) | IL284670B2 (he) |
| SG (1) | SG11202107397PA (he) |
| WO (1) | WO2020152568A1 (he) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114632019A (zh) * | 2020-11-30 | 2022-06-17 | 科思柔 | 用于治疗或改善皮肤的状况和外观的组合物和使用方法 |
| CN113480601B (zh) * | 2021-07-01 | 2022-09-23 | 中国医学科学院放射医学研究所 | 一种螯合铜离子的自组装多肽纳米水凝胶及其制备方法 |
| EP4385516A4 (en) * | 2021-08-12 | 2025-06-18 | Shenzhen Winkey Technology Co., Ltd. | Synthetic peptide, cosmetic composition or pharmaceutical composition and use thereof |
| CN113662877A (zh) * | 2021-09-07 | 2021-11-19 | 肽领生物科技(上海)有限公司 | 一种蓝酮肽修护精华液的制备方法 |
| CN114349823B (zh) * | 2022-01-25 | 2023-07-18 | 杭州禾泰健宇生物科技有限公司 | 一种双靶向多功能类肽化合物及其制备方法和应用 |
| CN114848887B (zh) * | 2022-05-20 | 2023-08-25 | 诺一迈尔(苏州)生命科技有限公司 | 一种纳米纤维敷料及其制备方法 |
| CN116098828B (zh) * | 2022-12-21 | 2024-08-02 | 深圳市维琪科技股份有限公司 | 四肽衍生物在制备用于皮肤修复紧致的组合物中的新用途 |
| CN115807050A (zh) * | 2022-12-30 | 2023-03-17 | 修实生物医药(南通)有限公司 | 一种短肽的生物合成方法 |
| KR20240154157A (ko) * | 2023-04-17 | 2024-10-25 | (주)케어젠 | 히알루론산 분해 지연 활성을 갖는 신규 펩타이드 및 이의 용도 |
| CN118791560B (zh) * | 2024-06-17 | 2025-02-25 | 广州慕可生物科技有限公司 | 一种具有调理皮脂分泌的肽类及其合成方法与应用 |
| CN119143846B (zh) * | 2024-11-15 | 2025-02-14 | 深圳市护家科技有限公司 | 皮肤护理物、多肽及其用途 |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003013569A2 (en) * | 2001-07-27 | 2003-02-20 | The Board Of Regents, The University Of Texas System | Use of thrombin-derived peptides for the therapy of chronic dermal ulcers |
| WO2003016520A1 (en) * | 2001-08-16 | 2003-02-27 | Kimberly-Clark Worldwide, Inc. | Anti-aging and wound healing compounds |
| WO2003030926A1 (en) * | 2001-10-05 | 2003-04-17 | Procyte Corporation | Stable solutions of peptide copper complexes and cosmetic and pharmaceutical formulations produced therefrom |
| WO2005042048A2 (en) * | 2003-10-22 | 2005-05-12 | Encelle, Inc. | Bioactive hydrogel compositions for regenerating connective tissue |
| US20050209131A1 (en) * | 2001-11-16 | 2005-09-22 | Singleton Laura C | Composition containing peptides complexed with a copper ion |
| WO2007032029A1 (en) * | 2005-09-13 | 2007-03-22 | Abburi Ramaiah | Agonist peptides of basic fibroblast growth factor (bfgf) and the method of reduction of wrinkle on skin, darkening of hair and acceleration of wound healing |
| WO2011157716A1 (en) * | 2010-06-14 | 2011-12-22 | Gene Signal International Sa | Novel peptides for wound healing |
| US20130108700A1 (en) * | 2011-11-02 | 2013-05-02 | Halscion, Inc. | Methods and compositions for wound treatment |
| WO2014126681A1 (en) * | 2013-02-14 | 2014-08-21 | Helix Biomedix Inc. | Short bio-active peptides for promoting wound healing |
| KR20160025954A (ko) * | 2014-08-28 | 2016-03-09 | (주)셀아이콘랩 | 펩타이드와 아미노산의 혼합물을 함유하는 아토피 개선용 화장료 조성물 |
| US20170224760A1 (en) * | 2016-02-04 | 2017-08-10 | ALASTIN Skincare, Inc. | Compositions and methods for invasive and non-invasive procedural skincare |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5155214A (en) | 1984-03-05 | 1992-10-13 | The Salk Institute For Biological Studies | Basic fibroblast growth factor |
| US5981606A (en) | 1991-03-01 | 1999-11-09 | Warner-Lambert Company | Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same |
| US5149691A (en) | 1991-03-12 | 1992-09-22 | Creative Biomolecules, Inc. | Issue repair and regeneration through the use of platelet derived growth factor (pdgf) in combination with dexamethasone |
| US5318973A (en) | 1993-06-07 | 1994-06-07 | Vyzkumny Ustav Pro Farmacii A Biochemii | Neuroprotective composition for preventing or treating of central nervous system impairment |
| US6800286B1 (en) | 1998-08-19 | 2004-10-05 | The Regents Of The University Of Colorado | Chimeric fibroblast growth factor proteins, nucleic acid molecules, and uses thereof |
| EP1640041A3 (de) * | 2004-09-24 | 2006-05-24 | Henkel Kommanditgesellschaft auf Aktien | Kosmetische und dermatologische Zusammensetzungen zur Behandlung reifer oder lichtgeschädigter Haut |
| JP6326601B2 (ja) | 2013-03-13 | 2018-05-23 | アンティース ソシエテ アノニム | 皮膚更新のためのペプチド及び前記ペプチドを使用する方法 |
-
2019
- 2019-01-21 CZ CZ201934A patent/CZ308845B6/cs not_active IP Right Cessation
-
2020
- 2020-01-20 EP EP20709701.5A patent/EP3914279A1/en not_active Withdrawn
- 2020-01-20 JP JP2021565146A patent/JP7193662B2/ja active Active
- 2020-01-20 CN CN202080009472.7A patent/CN113301910B/zh active Active
- 2020-01-20 IL IL284670A patent/IL284670B2/he unknown
- 2020-01-20 SG SG11202107397PA patent/SG11202107397PA/en unknown
- 2020-01-20 KR KR1020217026532A patent/KR20210120026A/ko not_active Ceased
- 2020-01-20 WO PCT/IB2020/050418 patent/WO2020152568A1/en not_active Ceased
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003013569A2 (en) * | 2001-07-27 | 2003-02-20 | The Board Of Regents, The University Of Texas System | Use of thrombin-derived peptides for the therapy of chronic dermal ulcers |
| WO2003016520A1 (en) * | 2001-08-16 | 2003-02-27 | Kimberly-Clark Worldwide, Inc. | Anti-aging and wound healing compounds |
| WO2003030926A1 (en) * | 2001-10-05 | 2003-04-17 | Procyte Corporation | Stable solutions of peptide copper complexes and cosmetic and pharmaceutical formulations produced therefrom |
| US20050209131A1 (en) * | 2001-11-16 | 2005-09-22 | Singleton Laura C | Composition containing peptides complexed with a copper ion |
| WO2005042048A2 (en) * | 2003-10-22 | 2005-05-12 | Encelle, Inc. | Bioactive hydrogel compositions for regenerating connective tissue |
| WO2007032029A1 (en) * | 2005-09-13 | 2007-03-22 | Abburi Ramaiah | Agonist peptides of basic fibroblast growth factor (bfgf) and the method of reduction of wrinkle on skin, darkening of hair and acceleration of wound healing |
| WO2011157716A1 (en) * | 2010-06-14 | 2011-12-22 | Gene Signal International Sa | Novel peptides for wound healing |
| US20130108700A1 (en) * | 2011-11-02 | 2013-05-02 | Halscion, Inc. | Methods and compositions for wound treatment |
| WO2014126681A1 (en) * | 2013-02-14 | 2014-08-21 | Helix Biomedix Inc. | Short bio-active peptides for promoting wound healing |
| KR20160025954A (ko) * | 2014-08-28 | 2016-03-09 | (주)셀아이콘랩 | 펩타이드와 아미노산의 혼합물을 함유하는 아토피 개선용 화장료 조성물 |
| US20170224760A1 (en) * | 2016-02-04 | 2017-08-10 | ALASTIN Skincare, Inc. | Compositions and methods for invasive and non-invasive procedural skincare |
Non-Patent Citations (8)
| Title |
|---|
| ALAN D. BORTHWICK,, 2,5-DIKETOPIPERAZINES: SYNTHESIS, REACTIONS, MEDICINAL CHEMISTRY, AND BIOACTIVE NATURAL PRODUCTS, 11 July 2012 (2012-07-11) * |
| ANA GOMES ET AL,, WOUND-HEALING PEPTIDES FOR TREATMENT OF CHRONIC DIABETIC FOOT ULCERS AND OTHER INFECTED SKIN INJURIES, 18 October 2017 (2017-10-18) * |
| GOROUHI AND H I MAIBACH F,, ROLE OF TOPICAL PEPTIDES IN PREVENTING OR TREATING AGED SKIN, 1 January 2009 (2009-01-01) * |
| MARIA B. WITTE ET AL,, ARGININE PHYSIOLOGY AND ITS IMPLICATION FOR WOUND HEALING, 1 November 2003 (2003-11-01) * |
| MEDURI A ET AL,, ROLE OF CYSTEINE IN CORNEAL WOUND HEALING AFTER PHOTOREFRACTIVE KERATECTOMY, 31 December 2009 (2009-12-31) * |
| REINALDO RAMOS ET AL,, WOUND HEALING ACTIVITY OF THE HUMAN ANTIMICROBIAL PEPTIDE LL37, 3 June 2011 (2011-06-03) * |
| YUN XIAO ET AL,, DIABETIC WOUND REGENERATION USING PEPTIDE-MODIFIED HYDROGELS TO TARGET RE-EPITHELIALIZATION, 4 October 2016 (2016-10-04) * |
| ZBYNEK SKLEN?R ET AL,, FORMULATION AND RELEASE OF ALAPTIDE FROM CELLULOSE-BASED HYDROGELS, 1 January 2012 (2012-01-01) * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7193662B2 (ja) | 2022-12-20 |
| WO2020152568A1 (en) | 2020-07-30 |
| JP2022513418A (ja) | 2022-02-07 |
| SG11202107397PA (en) | 2021-08-30 |
| IL284670B1 (he) | 2024-07-01 |
| EP3914279A1 (en) | 2021-12-01 |
| CN113301910A (zh) | 2021-08-24 |
| CZ201934A3 (cs) | 2020-07-29 |
| IL284670A (he) | 2021-08-31 |
| KR20210120026A (ko) | 2021-10-06 |
| CN113301910B (zh) | 2023-02-03 |
| CZ308845B6 (cs) | 2021-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7193662B2 (ja) | ペプチド成分の皮膚再生および治癒混合物とその使用 | |
| JP5814177B2 (ja) | 植物由来のエラスチン結合タンパク質リガンドおよびその使用方法 | |
| JP3706615B2 (ja) | 肌のしわ予防及び低減のための組成物 | |
| KR20020047214A (ko) | 진주층의 추출에 의해 진주층의 모든 성분을 포함하는조성물의 제조방법, 상기 방법을 이용하여 얻은 조성물,및 화장품 및 피부 의학에서의 이의 용도 | |
| CN115337221A (zh) | 一种有利于防脱生发的组合物及其制备方法和应用 | |
| JP5144690B2 (ja) | Ｐｌｇｆ−１を含む医薬品及び化粧品組成物 | |
| US9402906B2 (en) | Topical preparation containing NGF for inducing skin pigmentation and for the treatment of cutaneous dyschromias and vitiligo | |
| JP2010116405A6 (ja) | Ｐｌｇｆ−１を含む医薬品及び化粧品組成物 | |
| US20150224167A1 (en) | Composition for promoting wound healing | |
| WO2007002469A2 (en) | Therapeutic compositions and methods using transforming growth factor-beta mimics | |
| CN118949130A (zh) | 一种面部填充用胶原蛋白材料 | |
| KR102750087B1 (ko) | 펩타이드 혼합물을 함유하는 화장료 조성물 | |
| JP5306647B2 (ja) | 少なくとも１種類の天然Ａｃ−Ｎ−Ｓｅｒ−Ａｓｐ−Ｌｙｓ−Ｐｒｏテトラペプチドまたはその類似体の１つの、皮膚老化防止および再構築剤としての美容的使用 | |
| KR20150119244A (ko) | 피부의 표피 및 진피층을 자극하기 위한 국소적 조성물 | |
| US20060293227A1 (en) | Cosmetic compositions and methods using transforming growth factor-beta mimics | |
| CN108812639A (zh) | 一种细胞外基质冻干粉 | |
| US12233053B2 (en) | Adenosine A3 receptor antagonists for treating aging skin and wounds | |
| KR20210039636A (ko) | 피부 보습용 화장료 조성물 및 이의 제조방법 | |
| JP5767759B1 (ja) | ヘパリン含有組成物 | |
| US11793746B2 (en) | Intense skin hydration systems and methods | |
| KR20050006004A (ko) | 구리-펩타이드(Copper peptide)를 함유하는 화장료 조성물 | |
| KR20200062071A (ko) | 지방 생성을 자극하는 펩타이드, 조성 및 방법 | |
| KR20220110218A (ko) | 화장품 및 의약용 펩타이드 및 조성물 | |
| CN114929192A (zh) | 包含改善皮肤外观和再生的新型肽的用于局部施用的美容制剂 | |
| Rinky Kapoor et al. | QR 678 hair growth factors formulation-In vivo cellular toxicity & In vivo animal efficacy study. |